GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
Source: SeekingAlpha
2026-03-18 08:00:22 ET
In the previous article, "GSK: Depemokimab and Jemperli Lead the Next Wave" , I talked primarily about Q3 earnings, the impact of the data from the Phase 2 study [ NCT04165772 ] on Jemperli's long-term prospects, and why, in my opinion, declining Zejula sales are no longer putting pressure on its stock....
Read the full article on Seeking Alpha
For further details see:
GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
GlaxoSmithKline PLC
NASDAQ: GSK
GSK Trading
-0.44% G/L:
$51.91 Last:
2,379,187 Volume:
$52.17 Open:
GSK Latest News
March 13, 2026 11:44:00 am
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18-49 Years at Increased Risk
February 23, 2026 01:13:00 pm
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
GSK Stock Data
$120,291,791,432
2,019,018,428
0.4%
538
N/A
Pharmaceuticals
Healthcare
GB
London
